Giovanni Caforio (Photographer: Christopher Goodney/Bloomberg via Getty Images)

#AS­CO21: Bris­tol My­ers takes home the win in 1st late-stage study for LAG-3 path­way, set­ting up a US fil­ing

When Bris­tol My­ers Squibb dropped win­ning late-stage da­ta for its an­ti-LAG-3 drug in March, the re­sults of­fered new hope for an im­mune check­point path­way that had long lagged be­hind its bet­ter-known cousins. Now, the drug­mak­er is rolling out hard num­bers on that win, and it looks very promis­ing for an even­tu­al com­bo ap­proval along­side Op­di­vo.

A com­bo of Bris­tol My­ers’ LAG-3 in­hibitor re­latlimab and PD-1 block­er Op­di­vo post­ed a pro­gres­sion-free sur­vival of 10.12 months in pa­tients with metasta­t­ic or un­re­sectable melanoma com­pared with 4.63 months for pa­tients on Op­di­vo alone, ac­cord­ing to da­ta from the Phase II/III REL­A­TIV­I­TY-047 study set to be pre­sent­ed at AS­CO in June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.